Recent IPO pricing details for Attovia Therapeutics, a clinical-stage biotech developing ATTOBODY-based biologics for immune-mediated diseases, represent the key driver behind current market-implied odds. The company upsized its offering to 17 million shares at $17, targeting gross proceeds of $289 million and a post-IPO valuation near $731.5 million, with trading slated to begin August 5, 2026, on Nasdaq under ticker ATTO. Strong institutional backing from prior rounds—including Goldman Sachs Alternatives, Deep Track Capital, and others—alongside positive Phase 1 data for lead candidate ATTO-1310 and plans to advance assets against established therapies like Dupixent, supports trader expectations for closing market cap in the $700-800 million range. Closely matched probabilities across $600-900 million brackets reflect uncertainty around first-day trading volatility, biotech sector sentiment, and any last-minute demand shifts before the August 6 closing.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেডAttovia Therapeutics IPO Closing Market Cap
Attovia Therapeutics IPO Closing Market Cap
$700M-$800M 28%
$900M-$1B 27%
$1B+ 23%
$800M-$900M 21%
নতুন
নতুন
Aug 5, 2026
<$600M
3%
$600M-$700M
15%
$700M-$800M
28%
$800M-$900M
27%
$900M-$1B
27%
$1B+
23%
No IPO before October 2026
5%
$700M-$800M 28%
$900M-$1B 27%
$1B+ 23%
$800M-$900M 21%
নতুন
নতুন
Aug 5, 2026
<$600M
$43 Vol.
3%
$600M-$700M
$55 Vol.
15%
$700M-$800M
$70 Vol.
28%
$800M-$900M
$40 Vol.
27%
$900M-$1B
$40 Vol.
27%
$1B+
$483 Vol.
23%
No IPO before October 2026
$50 Vol.
5%
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Recent IPO pricing details for Attovia Therapeutics, a clinical-stage biotech developing ATTOBODY-based biologics for immune-mediated diseases, represent the key driver behind current market-implied odds. The company upsized its offering to 17 million shares at $17, targeting gross proceeds of $289 million and a post-IPO valuation near $731.5 million, with trading slated to begin August 5, 2026, on Nasdaq under ticker ATTO. Strong institutional backing from prior rounds—including Goldman Sachs Alternatives, Deep Track Capital, and others—alongside positive Phase 1 data for lead candidate ATTO-1310 and plans to advance assets against established therapies like Dupixent, supports trader expectations for closing market cap in the $700-800 million range. Closely matched probabilities across $600-900 million brackets reflect uncertainty around first-day trading volatility, biotech sector sentiment, and any last-minute demand shifts before the August 6 closing.
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
মার্কেট ওপেন হয়েছে: Aug 4, 2026, 9:51 PM ET
ভলিউম
$422শেষ তারিখ
Aug 5, 2026মার্কেট ওপেন হয়েছে
Aug 4, 2026, 9:51 PM ETResolver
0x69c47De9D...This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Recent IPO pricing details for Attovia Therapeutics, a clinical-stage biotech developing ATTOBODY-based biologics for immune-mediated diseases, represent the key driver behind current market-implied odds. The company upsized its offering to 17 million shares at $17, targeting gross proceeds of $289 million and a post-IPO valuation near $731.5 million, with trading slated to begin August 5, 2026, on Nasdaq under ticker ATTO. Strong institutional backing from prior rounds—including Goldman Sachs Alternatives, Deep Track Capital, and others—alongside positive Phase 1 data for lead candidate ATTO-1310 and plans to advance assets against established therapies like Dupixent, supports trader expectations for closing market cap in the $700-800 million range. Closely matched probabilities across $600-900 million brackets reflect uncertainty around first-day trading volatility, biotech sector sentiment, and any last-minute demand shifts before the August 6 closing.
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
ভলিউম
$422শেষ তারিখ
Aug 5, 2026মার্কেট ওপেন হয়েছে
Aug 4, 2026, 9:51 PM ETResolver
0x69c47De9D...Recent IPO pricing details for Attovia Therapeutics, a clinical-stage biotech developing ATTOBODY-based biologics for immune-mediated diseases, represent the key driver behind current market-implied odds. The company upsized its offering to 17 million shares at $17, targeting gross proceeds of $289 million and a post-IPO valuation near $731.5 million, with trading slated to begin August 5, 2026, on Nasdaq under ticker ATTO. Strong institutional backing from prior rounds—including Goldman Sachs Alternatives, Deep Track Capital, and others—alongside positive Phase 1 data for lead candidate ATTO-1310 and plans to advance assets against established therapies like Dupixent, supports trader expectations for closing market cap in the $700-800 million range. Closely matched probabilities across $600-900 million brackets reflect uncertainty around first-day trading volatility, biotech sector sentiment, and any last-minute demand shifts before the August 6 closing.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা